期刊文献+

Wnt5a在胰腺癌及癌前病变中的表达差异分析 被引量:3

Different expressions of Wnt5a in pancreatic cancer and precancerous lesions
下载PDF
导出
摘要 目的检测Wnt5a基因在不同胰腺组织中的蛋白表达水平,探讨其在胰腺导管腺癌(pancreatic ductal adenocar-cinoma,PDAC)发生中的作用,为胰腺癌的早期诊疗提供新线索。方法免疫组化SP法检测Wnt5a在21灶正常胰腺导管(normal pancreatic duct,NP)、73灶胰腺上皮内瘤变(pancreatic intraepithelial neoplasia,PanIN)-1、29灶PanIN-2、16灶PanIN-3、20例胰腺导管内乳头状黏液性肿瘤(intraductal papillary mucinous neoplasm,IPMN)腺瘤(IPMN-adenoma,IPMA)、13例IPMN交界瘤(IPMN-borderline,IPMB)、19例IPMN黏液癌(IPMN-carcinoma,IPMC)及50例PDAC组织中的蛋白表达。分析Wnt5a的表达与PDAC患者临床病理特征及患者术后生存期的关系。结果随着组织病变级别升高,Wnt5a表达逐渐增强,各组Wnt5a的免疫组化评分分别为NP(0)、PanIN-1(1.90±1.192)、PanIN-2(3.03±1.322)、PanIN-3(4.88±1.455)、IPMA(1.40±0.940)、IPMB(2.62±1.502)、IPMC(3.00±1.374)、PDAC(3.11±2.635)。Wnt5a的表达与肿瘤的增殖活度、远处转移、TNM分期及患者术后生存期相关(P<0.05),Wnt5a高表达组、低表达组的中位生存期分别为15个月和21个月(P=0.015)。结论 Wnt5a参与了PDAC的发生、发展;Wnt5a表达增强是PDAC的早期事件;Wnt5a的持续表达和过度表达影响了胰腺癌的增殖、侵袭和转移过程,并预示患者预后不良。 Objective To observe the expression of Wnt5a protein in different pancreatic tissues and to evaluate the role of Wnt5a in the carcinogenesis of pancreatic ductal adenocarcinoma(PDAC),so as to provide new clues for the diagnosis and treatment of pancreatic cancer.Methods Immunohistochemical SP method was used to examine the expressions of Wnt5a protein in 21 normal pancreatic duct tissues,73 pancreatic intraepithelial neoplasia(PanIN)-1 tissues,29 PanIN-2,16 PanIN-3 tissues,20 intraductal papillary mucinous neoplasm(IPMN) adenoma(IPMA) tissues,13 IPMN-borderline(IPMB) tissues,19 IPMN-carcinoma(IPMC) tissues and 50 PDAC tissues.The correlation of Wnt5a expression with clinicopathologic characteristics and postoperative survival of PDAC patients was analyzed.Results Wnt5a expression increased with the progression of the lesions in the following order: NP(0)→PanIN-1(1.90±1.192)→PanIN-2(3.03±1.322)→PanIN-3(4.88±1.455) or NP(0)→IPMA(1.40±0.940)→IPMB(2.62±1.502)→IPMC(3.00±1.374),and PDAC(3.11±2.635).Wnt5a expression was significantly correlated with tumor proliferation activity,distant metastasis,TNM staging and postoperative survival(P0.05).The median survival periods of PDAC patients with high and low Wnt5 expression were 15 months and 21 months,respectively(P=0.015).Conclusion Wnt5a is involved in the development and progression of PDAC.Enhancement of Wnt5a expression is an early event in PDAC;sustained or over-expression of Wnt5a may affect the proliferation,invasion and metastases of pancreatic cancer cells,and may indicate a poor prognosis.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2012年第3期265-269,共5页 Academic Journal of Second Military Medical University
基金 国家自然科学基金重大国际合作项目(30910103911)~~
关键词 胰腺导管腺癌 胰腺上皮内瘤变 导管内乳头状黏液性肿瘤 WNT5A pancreatic ductal adenocarcinoma pancreatic intraepithelial neoplasia intraductal papillary mucinous neoplasm Wnt5a
  • 相关文献

参考文献20

  • 1Kühl M.The WNT/calcium pathway:biochemical mediators,toolsand future requirements[J].Front Biosci,2004,9:967-974.
  • 2Prieve M G,Moon R T.Stromelysin-1 and mesothelin are differen-tially regulated by Wnt-5a and Wnt-1 in C57mg mouse mamma-ry epithelial cells[J].BMC Dev Biol,2003,3:2.
  • 3Iozzo R V,Eichstetter I,Danielson K G.Aberrant expression of thegrowth factor Wnt-5A in human malignancy[J].Cancer Res,1995,55:3495-3499.
  • 4Ripka S,Knig A,Buchholz M,Wagner M,Sipos B,Klppel G,etal.WNT5A-target of CUTL1 and potent modulator of tumor cellmigration and invasion in pancreatic cancer[J].Carcinogenesis,2007,28:1178-1187.
  • 5郑建明,朱明华,倪灿荣,刘晓红,黄玲,李兆申.TGF—β/Smads信号通路相关蛋白在胰腺上皮内瘤变和胰腺癌组织中的表达[J].胰腺病学,2004,4(4):204-209. 被引量:4
  • 6Tanaka M,Chari S,Adsay V,Fernandez-del Castillo C,FalconiM,Shimizu M,et al.International consensus guidelines for manage-ment of intraductal papillary mucinous neoplasms and mucinouscystic neoplasms of the pancreas[J].Pancreatology,2006,6(1-2):17-32.
  • 7Logan C Y,Nusse R.The Wnt signaling pathway in developmentand disease[J].Annu Rev Cell Dev Biol,2004,20:781-810.
  • 8Clevers H.Wnt/beta-catenin signaling in development and dis-ease[J].Cell,2006,127:469-480.
  • 9Bryja V,Cajnek L,Grahn A,Schulte G.Inhibition of endocytosisblocks Wnt signalling to beta-catenin by promoting dishevelleddegradation[J].Acta Physiol(Oxf),2007,190:55-61.
  • 10Polakis P.Wnt signaling and cancer[J].Genes Dev,2000,14:1837-1851.

二级参考文献10

  • 1Roel NUSSE.Wnt signaling in disease and in development[J].Cell Research,2005,15(1):28-32. 被引量:84
  • 2Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia:, a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol, 2001,25:579-586.
  • 3Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 1999, 18:5363-5372.
  • 4Biankin AV, Kench JG, Biankin SA, et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol, 2004, 28:1184-1192.
  • 5Subramanian G, Schwarz RE, Higgins L, et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotypel. Cancer Res, 2004, 64: 5200-5211.
  • 6Shi Y, Hata A, Lo RS, et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature, 1997,388:87-93.
  • 7Tascilar M, Skinner HG, Rosty C,et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res, 2001, 7:4115-4121.
  • 8Hata A, Shi Y, Massague J. TGF-beta signaling and cancer:structural and functional consequences of mutations in Smads.Mol Med Today, 1998,4:257-262.
  • 9Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.Mod Pathol, 2003, 16:902-912.
  • 10Miyazono K. TGF-beta/SMAD signaling and its involvement in tumor progression. Biol Pharm Bull, 2000, 23: 1125-1130.

共引文献3

同被引文献33

  • 1李铁军.牙源性角化囊肿是真性肿瘤吗?[J].北京大学学报(医学版),2007,39(1):6-9. 被引量:7
  • 2Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1) :9-29.
  • 3Hinton J, Callan R, Bodine C, et al. Potential epigenetic bio- markers for the diagnosis and prognosis of pancreatic ductal ade- -443 [J]. Expert Rev Mol Diagn, 2013, 13(5):431.
  • 4Gaujoux S, Brennan MF, Gonen M, et al. Cystic lesions of the pancreas: Changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period [ J ]. J Am Coil Surg, 2011, 212(4) :590-600, 600-593.
  • 5Chaturvedi P, Singh AP, Moniaux N, et al. MUC4 mucin poten- tiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins [ J ]. Mol Cancer Res, 2007, 5 (4) : 309- 320.
  • 6Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance [ J ]. Clin Cancer Res, 2001, 7 (12) :4033-4040.
  • 7Radhakrishnan P, Mohr AM, Grandgenett PM, et al. MicroRNA- 200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer [ J/ OL]. PLoS One, 2013 [ 2014-08-15 ]. http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3808362.
  • 8Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions[ J]. Am J Surg Pathol, 2001, 25 ( 5 ) :579-586.
  • 9Porchet N, Nguyen VC, Dufosse J, et al. Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs[ J]. Biochem Biophys Res Commun, 1991, 175 (2) : 414 -422.
  • 10Yin H, Liang Y, Yah Z, et al. Mutation spectrum in human colorectal cancers and potential functional relevance [ J ]. BMC Med Genet, 2013, 14(1) :32.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部